BioSapien secures $5.5M pre-Series A for its drug delivery platform

BioSapien, the patented drug delivery platform treating cancer "locally," announced a $5.5 million (20.2M AED) pre-Series A fundraise.
The capital will be used to fund the company's clinical trials in the UAE, with patient enrolments in Abu Dhabi set to begin in Q2 2025. Proceeds will also be allocated to increase product development and manufacturing and onboard new talent.
BioSapien's flagship product — MediChip — is a drug delivery, 3D-printed, slow-release delivery platform attachable to any tissue with minimal systemic side effects.
Local delivery means more of the drug stays in the tumor microenvironment to aid more efficient oncology, such as downsized tumors, alleviating symptoms, and preventing potentially life-altering surgeries. Local delivery also requires fewer quantities of drugs to be used while maintaining safety.
Initially, BioSapien is developing its platform for clinical trials in colorectal cancer patients, with the scope to branch out to other cancers (pancreatic, lung) and non-cancer indications such as opioids, hormones, biologics, and cell and gene therapies.
Funding 💰
Quotes 💬
About 🏢
💡Did you know?
You can take your DHArab experience to the next level with our Premium Membership.👉 Click here to learn more
🛠️Featured tool
Easy-Peasy
An all-in-one AI tool offering the ability to build no-code AI Bots, create articles & social media posts, convert text into natural speech in 40+ languages, create and edit images, generate videos, and more.
👉 Click here to learn more
